Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (6): 1669-1676.doi: 10.13481/j.1671-587X.20230636
• Review • Previous Articles Next Articles
Research progress in role of gut-liver axis in occurrence and development of atherosclerosis
-
Received:2022-09-08Online:2023-11-28Published:2023-12-22
CLC Number:
- R256.2
Cite this article
share this article
| 1 | LIBBY P. The changing landscape of atherosclerosis［J］. Nature， 2021， 592（7855）： 524-533. |
| 2 | POTHINENI N V K， SUBRAMANY S， KURIAKOSE K， et al. Infections， atherosclerosis， and coronary heart disease［J］. Eur Heart J， 2017， 38（43）： 3195-3201. |
| 3 | MENTAL DISORDERS COLLABORATORSGBD. Global， regional， and national burden of 12 mental disorders in 204 countries and territories， 1990-2019： a systematic analysis for the Global Burden of Disease Study 2019［J］.Lancet Psychiatry， 2022， 9（2）：137-150. |
| 4 | DAWSON P A. Impact of inhibiting ileal apical versus basolateral bile acid transport on cholesterol metabolism and atherosclerosis in mice［J］. Dig Dis， 2015， 33（3）： 382-387. |
| 5 | SHENG W， JI G， ZHANG L. The effect of lithocholic acid on the gut-liver axis［J］. Front Pharmacol， 2022， 13： 910493. |
| 6 | BRANDL K， KUMAR V， ECKMANN L. Gut-liver axis at the frontier of host-microbial interactions［J］. Am J Physiol Gastrointest Liver Physiol， 2017， 312（5）： G413-G419. |
| 7 | KATSIKI N， MANTZOROS C， MIKHAILIDIS D P. Adiponectin， lipids and atherosclerosis［J］. Curr Opin Lipidol， 2017， 28（4）： 347-354. |
| 8 | ALFADDAGH A， MARTIN S S， LEUCKER T M，et al.Inflammation and cardiovascular disease： from mechanisms to therapeutics［J］. Am J Prev Cardiol， 2020， 4： 100130. |
| 9 | LAURSEN I H， BANASIK K， HAUE A D， et al. Cohort profile： Copenhagen Hospital Biobank-Cardiovascular Disease Cohort （CHB-CVDC）： construction of a large-scale genetic cohort to facilitate a better understanding of heart diseases［J］. BMJ Open， 2021， 11（12）： e049709. |
| 10 | XU S W， KAMATO D， LITTLE P J， et al. Targeting epigenetics and non-coding RNAs in atherosclerosis： from mechanisms to therapeutics［J］. Pharmacol Ther， 2019， 196： 15-43. |
| 11 | GENG S， CHEN K Q， YUAN R X， et al. The persistence of low-grade inflammatory monocytes contributes to aggravated atherosclerosis［J］. Nat Commun， 2016， 7： 13436. |
| 12 | MIYAKE Y， YAMAMOTO K. Role of gut microbiota in liver diseases［J］. Hepatol Res，2013， 43（2）： 139-146. |
| 13 | WANG Z W， GUO X P， ZHANG Q， et al. Elimination of Ox-LDL through the liver inhibits advanced atherosclerotic plaque progression［J］. Int J Med Sci， 2021， 18（16）： 3652-3664. |
| 14 | WANG X M， YANG Y H， HUYCKE M M. Risks associated with enterococci as probiotics［J］. Food Res Int， 2020， 129： 108788. |
| 15 | TRIPATHI A， DEBELIUS J， BRENNER D A， et al. The gut-liver axis and the intersection with the microbiome［J］. Nat Rev Gastroenterol Hepatol， 2018， 15（7）： 397-411. |
| 16 | LENG J， TIAN H J， FANG Y， et al. Amelioration of non-alcoholic steatohepatitis by Atractylodes macrocephala polysaccharide， chlorogenic acid， and geniposide combination is associated with reducing endotoxin gut leakage［J］. Front Cell Infect Microbiol， 2022， 12： 827516. |
| 17 | PANDAK W M， KAKIYAMA G. The acidic pathway of bile acid synthesis： not just an alternative pathway［J］. Liver Res， 2019， 3（2）： 88-98. |
| 18 | FATTORUSSO A， DI GENOVA L， DELL’ISOLA G B， et al. Autism spectrum disorders and the gut microbiota［J］. Nutrients， 2019， 11（3）： 521. |
| 19 | JIE Z Y， XIA H H， ZHONG S L， et al. The gut microbiome in atherosclerotic cardiovascular disease［J］. Nat Commun， 2017， 8（1）： 845. |
| 20 | ZHANG S T， TIAN J， LEI M， et al. Association between dietary fiber intake and atherosclerotic cardiovascular disease risk in adults： a cross-sectional study of 14， 947 population based on the National Health and Nutrition Examination Surveys［J］. BMC Public Health， 2022， 22（1）： 1076. |
| 21 | DU Y， LI X X， SU C Y， et al. Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice［J］. Br J Pharmacol， 2020， 177（8）： 1754-1772. |
| 22 | ZOU F G， QIU Y， HUANG Y L， et al. Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function［J］. Cell Death Dis， 2021， 12（6）： 582. |
| 23 | MAZZAWI T. Gut microbiota manipulation in irritable bowel syndrome［J］.Microorganisms，2022，10（7）： 1332. |
| 24 | XU J， YANG Y J. Implications of gut microbiome on coronary artery disease［J］. Cardiovasc Diagn Ther， 2020， 10（4）： 869-880. |
| 25 | SANCHEZ-GIMENEZ R， AHMED-KHODJA W， MOLINA Y， et al. Gut microbiota-derived metabolites and cardiovascular disease risk： a systematic review of prospective cohort studies［J］. Nutrients， 2022， 14（13）： 2654. |
| 26 | TAN Y， ZHOU J Y， LIU C， et al. Association between plasma trimethylamine N-oxide and neoatherosclerosis in patients with very late stent thrombosis［J］. Can J Cardiol， 2020， 36（8）： 1252-1260. |
| 27 | MOHAMMADI A， VAHABZADEH Z， JAMALZADEH S， et al. Trimethylamine-N-oxide， as a risk factor for atherosclerosis， induces stress in J774A.1 murine macrophages［J］. Adv Med Sci， 2018， 63（1）： 57-63. |
| 28 | WITKOWSKI M， WEEKS T L， HAZEN S L. Gut microbiota and cardiovascular disease［J］. Circ Res， 2020， 127（4）： 553-570. |
| 29 | LIU H C， ZHU H J， XIA H， et al. Different effects of high-fat diets rich in different oils on lipids metabolism， oxidative stress and gut microbiota［J］. Food Res Int， 2021， 141： 110078. |
| 30 | DE AGUIAR VALLIM T Q， TARLING E J， EDWARDS P A. Pleiotropic roles of bile acids in metabolism［J］. Cell Metab， 2013， 17（5）： 657-669. |
| 31 | RAMÍREZ-PÉREZ O， CRUZ-RAMÓN V， CHINCHILLA-LÓPEZ P， et al. The role of the gut microbiota in bile acid metabolism［J］. Ann Hepatol， 2017， 16（1）： s15-s20. |
| 32 | YANG J Y， ZHANG T T， YU Z L， et al. Taurine alleviates trimethylamine N-oxide-induced atherosclerosis by regulating bile acid metabolism in ApoE－/－ mice［J］. J Agric Food Chem，2022， 70（18）： 5738-5747. |
| 33 | ZURKINDEN L， SVIRIDOV D， VOGT B， et al. Downregulation of Cyp7a1 by cholic acid and chenodeoxycholic acid in Cyp27a1/ApoE double knockout mice： differential cardiovascular outcome［J］. Front Endocrinol （Lausanne）， 2020， 11： 586980. |
| 34 | BUSTOS A Y， FONT DE VALDEZ G， FADDA S， et al. New insights into bacterial bile resistance mechanisms： the role of bile salt hydrolase and its impact on human health［J］. Food Res Int， 2018， 112： 250-262. |
| 35 | DEVKOTA S， WANG Y W， MUSCH M W， et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL-10－/－ mice［J］. Nature， 2012， 487（7405）： 104-108. |
| 36 | ISLAM K B， FUKIYA S， HAGIO M， et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats［J］. Gastroenterology， 2011， 141（5）： 1773-1781. |
| 37 | GUAN B Y， TONG J L， HAO H P， et al. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases［J］. Acta Pharm Sin B， 2022， 12（5）： 2129-2149. |
| 38 | CHIANG J Y L， FERRELL J M. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy［J］. Am J Physiol Gastrointest Liver Physiol， 2020， 318（3）： G554-G573. |
| 39 | HALKIAS C， DARBY W G， FELTIS B N， et al. Marine bile natural products as agonists of the TGR5 receptor［J］. J Nat Prod， 2021， 84（5）： 1507-1514. |
| 40 | MEMBERS A F， COMMITTEE FOR PRACTICE GUIDELINES CPG） E S C， NATIONAL CARDIAC SOCIETIES E C.2019 ESC/EAS guidelines for the management of dyslipidaemias：Lipid modification to reduce cardiovascular risk［J］. Atherosclerosis， 2019， 290： 140-205. |
| 41 | LEE J J， CHI G， FITZGERALD C， et al. Cholesterol efflux capacity and its association with adverse cardiovascular events： a systematic review and meta-analysis［J］. Front Cardiovasc Med， 2021， 8： 774418. |
| 42 | GRÜNER N， MATTNER J. Bile acids and microbiota： multifaceted and versatile regulators of the liver-gut axis［J］. Int J Mol Sci， 2021， 22（3）： 1397. |
| 43 | LAM V， SU J D， KOPROWSKI S， et al. Intestinal microbiota determine severity of myocardial infarction in rats［J］. FASEB J， 2012， 26（4）： 1727-1735. |
| 44 | MATSUO M.ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis［J］.J Pharmacol Sci，2022，148（2）：197-203. |
| 45 | ROCHA V Z， FOLCO E J， SUKHOVA G， et al. Interferon-gamma，a Th1 cytokine，regulates fat inflammation： a role for adaptive immunity in obesity［J］. Circ Res， 2008， 103（5）： 467-476. |
| 46 | LI H Z， WANG Q， ZHANG Y Y， et al. Onset of coronary heart disease is associated with HCMV infection and increased CD14 +CD16 + monocytes in a population of Weifang， China［J］. Biomed Environ Sci， 2020， 33（8）： 573-582. |
| 47 | TAN Y Y， YUE S R， LU A P， et al. The improvement of nonalcoholic steatohepatitis by Poria Cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis［J］. Phytomedicine， 2022， 103： 154208. |
| 48 | AZUMA R W， KADOWAKI T， EL-SAED A， et al. Associations of D-dimer and von Willebrand factor with atherosclerosis in Japanese and white men［J］. Acta Cardiol， 2010， 65（4）： 449-456. |
| 49 | ALLAN R B， DELANEY C L， MILLER M D， et al. A comparison of flow-mediated dilatation and peripheral artery tonometry for measurement of endothelial function in healthy individuals and patients with peripheral arterial disease［J］. Eur J Vasc Endovasc Surg， 2013， 45（3）： 263-269. |
| 50 | YAMASHITA T， KASAHARA K， EMOTO T，et al. Intestinal immunity and gut microbiota as therapeutic targets for preventing atherosclerotic cardiovascular diseases［J］. Circ J， 2015， 79（9）： 1882-1890. |
| 51 | LIU Z Q， SUN X， LIU Z B， et al. Phytochemicals in traditional Chinese medicine can treat gout by regulating intestinal flora through inactivating NLRP3 and inhibiting XOD activity［J］. J Pharm Pharmacol. 2022， 74（7）： 919-929. |
| 52 | BLEVINS H M， XU Y M， BIBY S， et al. The NLRP3 inflammasome pathway： a review of mechanisms and inhibitors for the treatment of inflammatory diseases［J］. Front Aging Neurosci， 2022， 14： 879021. |
| 53 | SONG Y J， ZHAO Y G， MA Y M， et al. Biological functions of NLRP3 inflammasome： a therapeutic target in inflammatory bowel disease［J］. Cytokine Growth Factor Rev， 2021， 60： 61-75. |
| 54 | LI X H， LIU L Z， CHEN L， et al. Aerobic exercise regulates FGF21 and NLRP3 inflammasome-mediated pyroptosis and inhibits atherosclerosis in mice［J］. PLoS One， 2022， 17（8）： e0273527. |
| 55 | O’CONNOR K D， BROPHY T， FONAROW G C，et al. Testing for coronary artery disease in older patients with new-onset heart failure： findings from get with the guidelines-heart failure［J］.Circ Heart Fail，2020，13（4）： e006963. |
| 56 | LI W， LUO J C， PENG F D， et al. Spatial metabolomics identifies lipid profiles of human carotid atherosclerosis［J］. Atherosclerosis， 2023， 364： 20-28. |
| 57 | CHEN R， CHEN T， ZHOU Z H， et al. Integrated pyroptosis measurement and metabolomics to elucidate the effect and mechanism of tangzhiqing on atherosclerosis［J］.Front Physiol， 2022，13： 937737. |
| 58 | WANG Y T， SUN X， QIU J W， et al. A UHPLC-Q-TOF-MS-based serum and urine metabolomics approach reveals the mechanism of Gualou-Xiebai herb pair intervention against atherosclerosis process in ApoE－/－ mice［J］. J Chromatogr B Analyt Technol Biomed Life Sci，2023， 1215： 123567. |
| 59 | 郁 晨. 基于“肝-肠”轴探讨冠心宁片抗西藏小型猪AS的作用及机制［D］. 杭州： 浙江中医药大学， 2020. |
| 60 | 段盈竹， 张 欢， 于 游， 等. 基于“木郁土壅”理论从“肝-肠轴学说”探析越鞠丸防治动脉粥样硬化的机制［J］. 中华中医药学刊， 2022， 40（10）： 99-102. |
| [1] | Meng QU,Shiya WENG,Hong ZHENG,Yan LI,Runze GAO,Shenggao WANG,Chunyan YU,Boxue CHEN,Zhiheng DONG. Protective effect of fermented red ginseng total saponins on rat myocardial interstitial fibroblasts cultured with high glucose and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1201-1208. |
| [2] | ZHAO Miao, WANG Yi, ZHANG Ying, FENG Yumei, CAO Yawen, JIANG Haisen, LI Wei. Improvement effect of curcumin on cognitive function in mice with sleep deprivation and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1373-1378. |
| [3] | WANG Su-xia，QIN Ling，TANG Yuan,WU Hai-di，LIN Shu-mei，XU Guo-liang. Meta-analysis on effectiveness and safety of zaleplon compared with zopiclone in treatment of insomnia [J]. Journal of Jilin University Medicine Edition, 2013, 39(1): 104-108. |
|
||
